IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

AMICUS THERAPEUTICS US, LLC and) AMICUS THERAPEUTICS, INC.,	
Plaintiffs,	
v.)	C.A. No. 22-1461-CJB ANDA CASE
TEVA PHARMACEUTICALS USA, INC., and TEVA PHARMACEUTICALS, INC.	Consolidated
Defendants.)	

STIPULATION AND ORDER TO AMEND SCHEDULING ORDER

WHEREAS the parties have conferred at length and agreed on reasonable changes to the Scheduling Order (D.I. 25, previously amended at D.I. 65 and 134) to accommodate the unique patent portfolio covering the drug at issue in this case, GALAFOLD, and allow discovery and trial to proceed as efficiently as possible; and

WHEREAS counsel for each party certifies that they sent a copy of this request to their respective clients in compliance with Local Civil Rule 16.4.

IT IS HEREBY STIPULATED AND AGREED by the parties, subject to the approval of the Court, that the Scheduling Order is amended as follows:

EVENT	CURRENT DEADLINE	PARTIES' PROPOSED DEADLINE
Thirty Month Stay Deadline	February 10, 2026	February 10, 2026
Deadline to Amend or	June 13, 2024	June 13, 2024
Supplement the		
Pleadings, Including by Joining		
Additional Parties and/or		
Asserting Additional Patents		
Claim Construction Hearing	N/A	N/A

EVENT	CURRENT DEADLINE	Parties' Proposed Deadline
Defendants serve on Plaintiffs a	28 days after Claim	August 22, 2024
"Final Election of Asserted Prior	Construction Order	1108021 ==, = 0 = 1
Art"		
Plaintiffs serve on Defendants a	14 days after service of	August 8, 2024
"Final Election of Asserted	Defendants' Final Election	
Claims"	of Asserted Prior Art	
Defendants' Amended Final	7 days after service of	N/A
Election of Asserted Prior Art	Plaintiffs' Final Election of	
	Asserted Claims	
Substantial Completion of	April 25, 2024	June 27, 2024
Document Production		
Completion of Fact Discovery	June 27, 2024	September 5, 2024
Final Deadline to Supplement	July 18, 2024	September 26, 2024
the Infringement Contentions		
and Invalidity Contentions		
Final Deadline to Supplement	August 1, 2024	October 10, 2024
Noninfringement Contentions		
Opening Expert Reports	September 12, 2024	October 31, 2024
Rebuttal Expert Reports	October 24, 2024	December 19, 2024
Reply Expert Reports	November 21, 2024	January 30, 2025
Close of Expert Discovery	January 16, 2025	March 20, 2025
Deadline to File <i>Daubert</i>	March 6, 2025	April 24, 2025
Motions		
Plaintiffs Provide to Defendants	56 days before submission	56 days before submission
a Draft Joint Pretrial Order	of Joint Proposed Pretrial	of Joint Proposed Pretrial
D 0 1 1 D 11 100	Order	Order
Defendants Provide to Plaintiffs	28 days before submission	28 days before submission
a Response to Plaintiffs' Draft	of Joint Proposed Pretrial	of Joint Proposed Pretrial
Joint Pretrial Order	Order	Order
Parties Submit Joint Proposed	21 days before proposed	21 days before proposed
Pretrial Order Pretrial Conference	Pretrial Conference	Pretrial Conference
rretrial Conference	March 26, 2025 at 3 p.m.	June 6, 2025 at 11:00 a.m.
Trial Begins (5 days)	April 7, 2025	June 23, 2025 at 9:00 a.m.

BARNES & THORNBURG LLP

/s/ Chad S.C. Stover

Chad S.C. Stover (No. 4919) 222 Delaware Avenue, Suite 1200 Wilmington, DE 19801 Tel: (302) 300-3474

Email: Chad.Stover@btlaw.com

John W. Cox, Ph.D.** Christina M. Baugh** Joshua M. Kalb** Lauren Baker** Anna Whitacre** 3340 Peachtree Road N.E., Suite 290 Atlanta, GA 30326 Tel. (404) 264-4092

Email: John.Cox@btlaw.com Email: Josh.Kalb@btlaw.com Email: Lauren.Baker@btlaw.com Email: Anna. Whitacre@btlaw.com

Mark C. Nelson** 2121 N. Pearl Street, Suite 700 Dallas, TX 75201 Tel: (214) 258-4140 Email: Mark.Nelson@btlaw.com

Heather B. Repicky** One Marina Park Drive, Suite 1530 Boston, MA 02210 Tel: (617) 316-5317 Email: Heather.Repicky@btlaw.com

Joshua E. Ney, Ph.D.** 1717 Pennsylvania Avenue N.W., Suite 500 Washington, DC 20006-4628 Tel: (734) 489-8004

** Admitted pro hac vice

Email: Josh.Ney@btlaw.com

Attorney for Plaintiffs Amicus Therapeutics US, LLC and Amicus Therapeutics, Inc.

SHAW KELLER LLP

/s/ Karen E. Keller

John W. Shaw (No. 3362) Karen E. Keller (No. 4489) Nathan R. Hoeschen (No. 6232) Andrew E. Russell (No. 5382) SHAW KELLER LLP I.M. Pei Building 1105 N. Market Street, 12th Floor Wilmington, DE 19801 kkeller@shawkeller.com nhoeschen@shawkeller.com jshaw@shawkeller.com arussell@shawkeller.com

Kurt A. Mathas Kevin Boyle WINSTON & STRAWN LLP 35 West Wacker Dr. Chicago, IL 60601-9703 kmathas@winston.com kboyle@winston.com

Claire Fundakowski WINSTON & STRAWN LLP 1901 L Street NW Washington, DC 20036 cfundakowski@winston.com

Attorneys for Defendants Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals. Inc

KRATZ & BARRY LLP

/s/ R. Touhey Myer

R. Touhey Myer (No. 5939) 800 N. West Street Wilmington, DE 19801 (302) 544-9100 tmyer@kratzandbarry.com

Timothy H. Kratz George J. Barry III 1050 Crown Pointe Parkway, Suite 500 Atlanta, GA 30338

tkratz@kratzandbarry.com gbarry@kratzandbarry.com

Michael P. Hogan KRATZ & BARRY LLP 325 Chestnut Street, Suite 883, #259 Philadelphia, PA 19106 mhogan@kratzandbarry.com

Attorney for Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.

IT IS SO ORDERED this 12th day of April, 2024.

The Honorable Christopher J. Burke United States Magistrate Judge